The implantable cardioverter-defibrillator (ICD) is the mainstay therapy for primary prevention of sudden cardiac death in patients with heart failure with a reduced ejection fraction. Current indications for prophylactic ICD are based on the results of randomized controlled trials dating back to 15-20 years ago, which have usually enrolled highly selected patients with few comorbidities and only a small number of patients aged >75 years. Existing literature suggest an age-dependent attenuation of the efficacy of the ICD. Because of the ageing of the population, there is need for data addressing device efficacy among older patients that also considers the impact of geriatric syndromes on health status. The assessment of frailty may be of value in identifying elderly patients who may or may not benefit from ICD placement for primary prevention of sudden cardiac death.
THE EFFICACY OF IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR (ICD) FOR PRIMARY PREVENTION OF SUDDEN CARDIAC DEATH (SCD) IN PATIENTS WITH HEART FAILURE (HF) WITH EJECTION FRACTION (EF) 35 PERCENT OR LESS IS NOT AFFECTED BY THE METHOD USED TO ESTIMATE THE EF: INSIGHTS FROM THE SUDDEN CARDIAC DEATH IN HEART FAILURE TRIAL (SCD-HEFT)
